Table 2.
The baseline study population characteristics according to the quartile of TNFR2
| Characteristics | Quartile of TNFR2, Range, pg/ml | P for Linear Trend | |||
|---|---|---|---|---|---|
| Quartile 1 (n=399) | Quartile 2 (n=401) | Quartile 3 (n=393) | Quartile 4 (n=397) | ||
| (1186–2248) | (2249–2573) | (2574–2971) | (2972–8253) | ||
| Men, % | 42.4 | 45.1 | 52.7 | 55.7 | <0.001 |
| Age baseline, yr | 57.3 (3.8) | 57.8 (3.9) | 58.4 (3.8) | 58.7 (3.7) | <0.001 |
| Height, m | 169.3 (8.9) | 170.0 (8.6) | 171.4 (8.2) | 171.9 (9.0) | <0.001 |
| Weight, kg | 75.6 (14.2) | 78.1 (13.5) | 80.9 (13.3) | 83.6 (15.0) | <0.001 |
| Body mass index, kg/m2 | 26.3 (3.8) | 26.9 (3.6) | 27.5 (3.8) | 28.2 (4.4) | <0.001 |
| hsCRP, mg/L | 0.91 (0.52–1.58) | 0.99 (0.57–1.83) | 1.37 (0.73–2.43) | 1.59 (0.88–3.47) | <0.001 |
| Systolic BP, mmHg | 127.4 (17.7) | 130.6 (18.0) | 128.5 (17.1) | 131.1 (17.1) | 0.02 |
| Diastolic BP, mmHg | 82.5 (10.1) | 83.9 (10.2) | 83.1 (9.6) | 83.9 (9.2) | 0.13 |
| Fasting glucose, mg/dl | 95.79 (8.83) | 95.50 (8.63) | 95.86 (8.13) | 96.07 (9.09) | 0.49 |
| Hemoglobin A1c, % | 5.52 (0.32) | 5.53 (0.33) | 5.51 (0.33) | 5.57 (0.35) | 0.09 |
| HDL cholesterol, mg/dl | 63.83 (16.28) | 62.01 (15.33) | 56.85 (16.01) | 54.44 (15.64) | <0.001 |
| LDL cholesterol, mg/dl | 140.44 (35.44) | 142.61 (30.57) | 140.23 (34.01) | 142.83 (32.49) | 0.52 |
| Triglycerides, mg/dl | 79.7 (62.0–106.2) | 88.5 (62.5–123.9) | 97.4 (70.8–132.8) | 97.4 (70.8–141.6) | <0.001 |
| Albumin-to-creatinine ratio, mg/g | 2.21 (0.88–4.69) | 2.12 (0.88–5.22) | 1.57 (0.88–4.34) | 2.21 (0.88–4.78) | 0.93 |
| ACEi, % | 1.5 | 0.7 | 2.3 | 2.5 | 0.12 |
| ARB, % | 7.0 | 6.5 | 9.4 | 10 | 0.05 |
| NSAIDs, % | 1.5 | 1.5 | 4.1 | 2.3 | 0.15 |
| Current smoker, % | 14 | 18 | 22 | 27 | <0.001 |
| Alcohol consumption, % | 33 | 32 | 22 | 22 | <0.001 |
| Absolute mGFR, ml/min | 106.2 (20.0) | 104.9 (19.0) | 103.2 (19.7) | 100.7 (20.8) | <0.001 |
| mGFR, ml/min per 1.73 m2 | 98.6 (13.8) | 95.8 (13.0) | 92.3 (14.0) | 88.6 (14.5) | <0.001 |
| eGFR by CKD-EPI equation, ml/min per 1.73 m2 | |||||
| eGFRcre | 97.6 (8.2) | 95.3 (8.8) | 94.2 (9.2) | 92.2 (11.0) | <0.001 |
| eGFRcys | 112.3 (8.9) | 108.7 (8.8) | 104.5 (9.9) | 96.2 (14.4) | <0.001 |
| eGFRcrecys | 109.1 (9.4) | 105.3 (9.4) | 101.8 (9.7) | 95.8 (12.5) | <0.001 |
The Renal Iohexol-Clearance Survey Follow-Up Study. Numbers are presented as mean (SD), median (interquartile range), and percentage. TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; mGFR, measured GFR; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFRcre, eGFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.